M0674 / EMD Serono - LARVOL DELTA

The novel trispecific tumor-conditional TRAIL-R agonist M0674 induces tumor cell apoptosis and deepens therapeutic efficacy of systemic and targeted chemotherapies (AACR 2025) - "MUC1-dependent single-agent activity and combination benefits with docetaxel are observed in three out of five nsqNSCLC PDX models that do not respond to docetaxel alone. Additionally, five out of six PDAC PDX models exhibit a strong combination benefit of M0674 with gemcitabine. M0674 induces tumor-specific hyperclustering of TRAIL-R1 and R2 by binding to TA-MUC1, effectively triggering apoptosis in tumor cells without affecting healthy cells. The robust preclinical antitumor activity across various cancer types highlights the potential of M0674 as a safe and effective combination partner for systemic chemotherapies and ADCs."

Clinical • Trispecific • Tumor cell • Lung Non-Squamous Non-Small Cell Cancer • Oncology • Solid Tumor • CEACAM5 • MUC1 • TNFRSF10A • TNFRSF10B